Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial tissue. Overall benefits of one drug over the other is neutral in this generally unstable population. In pre-clinical trials, ticagrelor showed secondary effects, involving the release of adenosine to heart muscle where the demand for blood was increased due to a stress condition. Blood flow was increased, potentially preventing potential damage.

This study will compare ticagrelor, currently only approved for use in ACS patients, against clopidogrel by measuring the myocardial blood flow(MBF) during stress to validate this phenomenon. The effect on blood flow will be measurable by using two specific doses of adenosine as the pharmacologic stress and correlating with measurements of blood flow using positron emission tomography (PET) nuclear imaging.

This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

NCT02233790

Myocardial Infarction No-Reflow Phenomenon

UNKNOWN PHASE4

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872

Acute Coronary Syndrome

COMPLETED PHASE3

Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR

NCT05978726

Coronary Heart Disease

COMPLETED

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

NCT02469740

Myocardial Ischemia Coronary Artery Disease Endothelial Dysfunction

COMPLETED PHASE4

Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes

NCT04057300

Acute Coronary Syndrome

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

stable CAD management

Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

Blinded administration of ticagrelor for 10 days

Clopidogrel

Intervention Type DRUG

Blinded administration of clopidogrel and placebo for 10 days

CAD comparison group

Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.

Group Type ACTIVE_COMPARATOR

Ticagrelor

Intervention Type DRUG

Blinded administration of ticagrelor for 10 days

Clopidogrel

Intervention Type DRUG

Blinded administration of clopidogrel and placebo for 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

Blinded administration of ticagrelor for 10 days

Intervention Type DRUG

Clopidogrel

Blinded administration of clopidogrel and placebo for 10 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BrilintaTM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years old
2. Stable coronary artery disease on stable medical treatment.
3. BMI equal to or less than 30 kg/m2
4. No clinically significant abnormalities in baseline laboratory work
5. No clinically significant arrhythmias on baseline 12-lead electrocardiogram
6. Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment.

Exclusion Criteria

1. Any contraindication against the use of clopidogrel, ticagrelor and/or ASA.
2. Oral anticoagulation therapy.
3. History of intracranial bleeding.
4. Recent or active pathological bleeding, such as peptic ulcer.
5. Moderate or severe hepatic impairment.
6. History or risk of bradycardia.
7. Known second- or third-degree AV block without pacemaker
8. Dyspnea (NYHA III/IV), wheezing asthma or COPD.
9. Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent.
10. Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent.
11. Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent.
12. Any scheduled surgery during the trial period, including dental.
13. Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer.
14. Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
15. Known hypersensitivity to the investigational drug or any of its components.
16. Known hypersensitivity to adenosine.
17. Lactose intolerance
18. Breastfeeding or pregnancy.
19. Claustrophobia or inability to lie still in a supine position
20. Unwillingness to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No